Using Antithrombin III for Patients with Liver Cirrhosis
Author Information
Author(s): Brunner R, Madl C, Druml W, Holzinger U
Primary Institution: Medical University of Vienna, Austria
Hypothesis
Single-dose application of antithrombin III prolongs filter lifetime during renal and liver replacement therapy in critically ill patients with advanced liver cirrhosis without causing additional bleeding problems.
Conclusion
Single-dose application of antithrombin III is effective and safe for anticoagulation in critically ill patients with advanced liver cirrhosis.
Supporting Evidence
- Data were available for 13 CRRT, 14 IHD, and six MARS filters.
- Mean filter lifetimes were 44.0 hours for CRRT, 4.7 hours for IHD, and 4.6 hours for MARS.
- Bleeding complications were not observed during IHD, MARS, and CRRT.
Takeaway
Doctors used a special medicine called antithrombin III to help patients with liver problems during treatment, and it worked well without causing bleeding.
Methodology
Retrospective analysis of data from 33 extracorporeal therapies in 9 patients with advanced liver cirrhosis.
Limitations
The study is retrospective and lacks prospective controlled trials.
Participant Demographics
Critically ill patients with advanced liver cirrhosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website